Cargando…

Effects of Levosimendan on cardiac function, size and strain in heart failure patients

Levosimendan improves cardiac function in heart failure populations; however, its exact mechanism is not well defined. We analysed the short-term impact of levosimendan in heart failure patients with ischemic and non-ischemic cardiomyopathy (CMP) using multiparametric cardiac magnetic resonance (CMR...

Descripción completa

Detalles Bibliográficos
Autores principales: Beitzke, D., Gremmel, F., Senn, D., Laggner, R., Kammerlander, A., Wielandner, A., Nolz, R., Hülsmann, M., Loewe, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969546/
https://www.ncbi.nlm.nih.gov/pubmed/33103224
http://dx.doi.org/10.1007/s10554-020-02077-z
_version_ 1783666246463520768
author Beitzke, D.
Gremmel, F.
Senn, D.
Laggner, R.
Kammerlander, A.
Wielandner, A.
Nolz, R.
Hülsmann, M.
Loewe, C.
author_facet Beitzke, D.
Gremmel, F.
Senn, D.
Laggner, R.
Kammerlander, A.
Wielandner, A.
Nolz, R.
Hülsmann, M.
Loewe, C.
author_sort Beitzke, D.
collection PubMed
description Levosimendan improves cardiac function in heart failure populations; however, its exact mechanism is not well defined. We analysed the short-term impact of levosimendan in heart failure patients with ischemic and non-ischemic cardiomyopathy (CMP) using multiparametric cardiac magnetic resonance (CMR). We identified 33 patients with ischemic or non-ischemic CMP who received two consecutive CMR scans prior to and within one week after levosimendan administration. Changes in LV ejection fraction (LVEF) and LV volumes, as well as changes in strain rates, were measured prior to and within one week after levosimendan infusion. LV scarring, based on late gadolinium enhancement (LGE), was correlated to changes in LV size and strain rates. Both LV endiastolic (EDV) and endsystolic volumes (ESV) significantly decreased (EDV: p=0,001; ESV: p=0,002) after levosimendan administration, with no significant impact on LVEF (p=0.41), cardiac output (p=0.61), and strain rates. Subgroup analyses of ischemic or non-ischemic CMP showed no significant differences between the groups in terms of short-term LV reverse remodeling. The presence and extent of scarring in LGE did not correlate with changes in LV size and strain rates. CMR is able to monitor cardiac effects of levosimendan infusion. Short-term follow-up of a single levosimendan infusion using CMR shows a significant decrease in LV size, but no impact on LVEF or strain measurements. There was no difference between patients with ischemic or non-ischemic CMP. Quantification of LV scarring in CMR is not able to predict changes in LV size and strain rates in response to levosimendan.
format Online
Article
Text
id pubmed-7969546
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-79695462021-04-05 Effects of Levosimendan on cardiac function, size and strain in heart failure patients Beitzke, D. Gremmel, F. Senn, D. Laggner, R. Kammerlander, A. Wielandner, A. Nolz, R. Hülsmann, M. Loewe, C. Int J Cardiovasc Imaging Original Paper Levosimendan improves cardiac function in heart failure populations; however, its exact mechanism is not well defined. We analysed the short-term impact of levosimendan in heart failure patients with ischemic and non-ischemic cardiomyopathy (CMP) using multiparametric cardiac magnetic resonance (CMR). We identified 33 patients with ischemic or non-ischemic CMP who received two consecutive CMR scans prior to and within one week after levosimendan administration. Changes in LV ejection fraction (LVEF) and LV volumes, as well as changes in strain rates, were measured prior to and within one week after levosimendan infusion. LV scarring, based on late gadolinium enhancement (LGE), was correlated to changes in LV size and strain rates. Both LV endiastolic (EDV) and endsystolic volumes (ESV) significantly decreased (EDV: p=0,001; ESV: p=0,002) after levosimendan administration, with no significant impact on LVEF (p=0.41), cardiac output (p=0.61), and strain rates. Subgroup analyses of ischemic or non-ischemic CMP showed no significant differences between the groups in terms of short-term LV reverse remodeling. The presence and extent of scarring in LGE did not correlate with changes in LV size and strain rates. CMR is able to monitor cardiac effects of levosimendan infusion. Short-term follow-up of a single levosimendan infusion using CMR shows a significant decrease in LV size, but no impact on LVEF or strain measurements. There was no difference between patients with ischemic or non-ischemic CMP. Quantification of LV scarring in CMR is not able to predict changes in LV size and strain rates in response to levosimendan. Springer Netherlands 2020-10-24 2021 /pmc/articles/PMC7969546/ /pubmed/33103224 http://dx.doi.org/10.1007/s10554-020-02077-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Paper
Beitzke, D.
Gremmel, F.
Senn, D.
Laggner, R.
Kammerlander, A.
Wielandner, A.
Nolz, R.
Hülsmann, M.
Loewe, C.
Effects of Levosimendan on cardiac function, size and strain in heart failure patients
title Effects of Levosimendan on cardiac function, size and strain in heart failure patients
title_full Effects of Levosimendan on cardiac function, size and strain in heart failure patients
title_fullStr Effects of Levosimendan on cardiac function, size and strain in heart failure patients
title_full_unstemmed Effects of Levosimendan on cardiac function, size and strain in heart failure patients
title_short Effects of Levosimendan on cardiac function, size and strain in heart failure patients
title_sort effects of levosimendan on cardiac function, size and strain in heart failure patients
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969546/
https://www.ncbi.nlm.nih.gov/pubmed/33103224
http://dx.doi.org/10.1007/s10554-020-02077-z
work_keys_str_mv AT beitzked effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients
AT gremmelf effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients
AT sennd effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients
AT laggnerr effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients
AT kammerlandera effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients
AT wielandnera effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients
AT nolzr effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients
AT hulsmannm effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients
AT loewec effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients